Allworth Financial LP Has $2.93 Million Stake in Colgate-Palmolive Company $CL

Allworth Financial LP raised its position in shares of Colgate-Palmolive Company (NYSE:CL) by 31.8% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 37,102 shares of the company’s stock after acquiring an additional 8,959 shares during the period. Allworth Financial LP’s holdings in Colgate-Palmolive were worth $2,932,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the company. ProShare Advisors LLC increased its holdings in Colgate-Palmolive by 11.0% in the 3rd quarter. ProShare Advisors LLC now owns 2,047,542 shares of the company’s stock worth $163,681,000 after buying an additional 202,379 shares during the period. Providence Capital Advisors LLC acquired a new stake in shares of Colgate-Palmolive during the 3rd quarter worth approximately $5,373,000. Envestnet Asset Management Inc. grew its stake in shares of Colgate-Palmolive by 18.0% during the 3rd quarter. Envestnet Asset Management Inc. now owns 800,554 shares of the company’s stock worth $63,996,000 after purchasing an additional 122,202 shares during the period. Citigroup Inc. grew its stake in shares of Colgate-Palmolive by 43.7% during the 3rd quarter. Citigroup Inc. now owns 1,346,590 shares of the company’s stock worth $107,646,000 after purchasing an additional 409,710 shares during the period. Finally, TD Waterhouse Canada Inc. grew its stake in shares of Colgate-Palmolive by 248.5% during the 3rd quarter. TD Waterhouse Canada Inc. now owns 87,410 shares of the company’s stock worth $6,909,000 after purchasing an additional 62,327 shares during the period. Institutional investors and hedge funds own 80.41% of the company’s stock.

Colgate-Palmolive Stock Down 0.7%

Shares of NYSE:CL opened at $88.20 on Friday. The business has a 50-day moving average price of $86.30 and a 200 day moving average price of $84.68. The company has a current ratio of 1.02, a quick ratio of 0.67 and a debt-to-equity ratio of 16.33. The company has a market capitalization of $70.76 billion, a price-to-earnings ratio of 34.32, a PEG ratio of 4.57 and a beta of 0.31. Colgate-Palmolive Company has a 12-month low of $74.54 and a 12-month high of $99.33.

Colgate-Palmolive (NYSE:CL) last announced its quarterly earnings data on Friday, May 1st. The company reported $0.97 EPS for the quarter, topping analysts’ consensus estimates of $0.94 by $0.03. Colgate-Palmolive had a return on equity of 386.76% and a net margin of 10.04%.The business had revenue of $5.32 billion during the quarter, compared to the consensus estimate of $5.22 billion. During the same period in the previous year, the company posted $0.91 earnings per share. The business’s revenue for the quarter was up 8.4% on a year-over-year basis. Sell-side analysts expect that Colgate-Palmolive Company will post 3.82 EPS for the current year.

Colgate-Palmolive Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, May 15th. Stockholders of record on Monday, April 20th were issued a $0.53 dividend. The ex-dividend date of this dividend was Monday, April 20th. This is an increase from Colgate-Palmolive’s previous quarterly dividend of $0.52. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.4%. Colgate-Palmolive’s dividend payout ratio is presently 82.49%.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on CL. JPMorgan Chase & Co. raised their price objective on Colgate-Palmolive from $95.00 to $96.00 and gave the company an “overweight” rating in a report on Monday, May 4th. Barclays raised their price objective on Colgate-Palmolive from $79.00 to $80.00 and gave the company an “equal weight” rating in a report on Tuesday, May 5th. Royal Bank Of Canada restated an “outperform” rating and issued a $102.00 price objective on shares of Colgate-Palmolive in a report on Monday, May 4th. Weiss Ratings upgraded Colgate-Palmolive from a “hold (c)” rating to a “hold (c+)” rating in a report on Monday, May 4th. Finally, Wells Fargo & Company reduced their price target on Colgate-Palmolive from $100.00 to $92.00 and set an “equal weight” rating on the stock in a report on Wednesday, April 8th. Twelve equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $95.88.

Colgate-Palmolive News Roundup

Here are the key news stories impacting Colgate-Palmolive this week:

• Positive Sentiment: Zacks also highlighted Colgate’s innovation strategy as a support for market share gains, with premium launches, pricing actions and science-based products helping growth in oral care and pet nutrition. Why Colgate’s Innovation Strategy Is Fueling Market Share Gains
• Neutral Sentiment: Analysts lowered near-term and longer-term EPS estimates, but the changes were relatively modest and the new forecasts still point to continued earnings growth over the next few years.
• Negative Sentiment: Zacks Research cut FY2026 EPS to $3.80 from $3.89, FY2027 to $4.01 from $4.15, FY2028 to $4.39 from $4.44, and reduced several quarterly estimates, signaling a slightly less optimistic profit outlook for Colgate-Palmolive. Analyst estimate cuts for Colgate-Palmolive

Colgate-Palmolive Company Profile

Colgate-Palmolive Company is a global consumer products company with a long history in household and personal care categories. The business traces its roots to the early 19th century and has evolved into a multinational manufacturer and marketer of everyday consumer goods focused on health, hygiene and home care.

The company’s core activities center on oral care, personal care, home care and pet nutrition. Its product portfolio includes toothpaste, toothbrushes and mouthwash in oral care; soaps, body washes and deodorants in personal care; dishwashing liquids, surface cleaners and other household products in home care; and scientifically formulated pet foods under its pet nutrition business.